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Introduction
Following major changes in technique since the early 
iterations of endoluminal fundoplication (ELF) and tran-
soral incisionless fundoplication (TIF) 1.0 (gastrogastric 
fundoplication), the TIF 2.0 procedure (esophagogastric 
fundoplication) performed with the EsophyX
2
 device 
(EndoGastric Solutions, Redmond, WA) has emerged as 
a safe and effective therapy for chronic gastroesophageal 
reflux disease (GERD) in patients with minimal anatom-
ical deterioration of the gastroesophageal junction and 
the diaphragmatic hiatus. Other studies have documented 
the lack of serious adverse events (SAEs) and demon-
strated the ability of TIF 2.0 to eliminate GERD symptoms, 
heal reflux esophagitis, normalize or reduce pathological 
distal esophageal acid exposure, and reduce proton pump 
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Abstract
Background. Questions remain about the therapeutic durability of transoral incisionless fundoplication (TIF). In this 
study, clinical outcomes were evaluated at 5 years post-TIF 2.0. Methods. A total of 63 chronic gastroesophageal reflux 
disease (GERD) sufferers with troublesome symptoms refractory to proton pump inhibitor (PPI) therapy, absent or ≤2 
cm hiatal hernia, and abnormal esophageal acid exposure were randomized to the TIF group or PPI group. Following 
the 6-month evaluation, all patients in the PPI group elected for crossover to TIF; therefore, all 63 patients underwent 
TIF 2.0 with EsophyX
2
 device. Primary outcome was elimination of daily troublesome regurgitation and atypical 
symptoms at the 5-year follow-up. Secondary outcomes were improvement in symptom scores, PPI use, reoperations, 
and patient health satisfaction. The cost-effectiveness of TIF 2.0 was also estimated. Results. Of 63 patients, 60 were 
available at 1 year, 52 at 3 years, and 44 at 5 years for evaluation. Troublesome regurgitation was eliminated in 88% 
of patients at 1 year, 90% at 3 years, and 86% at 5 years. Resolution of troublesome atypical symptoms was achieved 
in 82% of patients at 1 year, 88% at 3 years, and 80% at 5 years. No serious adverse events occurred. There were 3 
reoperations by the end of the 5-year follow-up. At the 5-year follow-up, 34% of patients were on daily PPI therapy 
as compared with 100% of patients at screening. The total GERD Health-related quality-of-life score improved by 
decreasing from 22.2 to 6.8 at 5 years (P < .001). Conclusion. In this patient population, the TIF 2.0 procedure provided 
safe and sustained long-term elimination of troublesome GERD symptoms.
Keywords
transoral incisionless fundoplication (TIF), regurgitation, EsophyX, atypical GERD symptoms, proton pump inhibitor 
(PPI), heartburn
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inhibitor (PPI) use in a subset of chronic GERD 
patients.1-5 Despite these successes, the durability of 
these outcomes remained in question.
The TIF 2.0 EsophyX vs Medical PPI Open label 
(TEMPO) trial is a multicenter, controlled, randomized 
study with 3 prior publications.3-5 In these reports, the 
superiority of the TIF 2.0 procedure compared with high-
dose PPIs in a select group of chronic GERD sufferers 
with small or absent hiatal hernias was established. The 
safety of the procedure, a very low incidence of associ-
ated postfundoplication side effects, and sustained posi-
tive outcomes up to 3 years post-TIF 2.0 have been 
reported.3-5
The outstanding feature for the cohort of patients 
included in this study is that they represented ideal surgi-
cal candidates for an antireflux procedure because of 
their longstanding documented reflux, incomplete 
response to optimized medical therapy, and willingness 
to seek a surgical cure. Analysis of the 5-year follow-up 
data offers the opportunity to assess the durability of 
symptomatic control, quality-of-life outcomes, reopera-
tion rates post-TIF, PPI use, and patient satisfaction. This 
is the first study to assess long-term clinical outcomes 
beyond 3 years in patients in the United States. The 
authors expected that the determination of reoperation 
rates 5 years post-TIF could offer preliminary cost com-
parisons for the TIF procedure versus the more traditional 
laparoscopic Nissen fundoplication (LNF). Finally, we 
hoped to use the results of this long-term follow-up to 
propose a role for the TIF procedure in the antireflux 
armamentarium for select patients.
Methods
Study Design
This was a randomized, multicenter, open-label study, 
with a crossover arm, carried out at 7 community-based 
practices in the United States. The study design has been 
described in detail previously.3-5 Briefly, eligible patients 
were randomly assigned to receive either TIF 2.0 or max-
imum dose PPI therapy with a target allocation ratio of 
2:1. After their 6-month evaluation, all patients in the PPI 
arm elected to undergo the TIF 2.0 procedure. Therefore, 
for the purpose of this report, each patient served as his or 
her own control as compared with the baseline assess-
ment. The institutional review board of the participating 
institutions approved the extension of the study, and writ-
ten consent was obtained from all participants prior to the 
5-year follow-up. The study was prospectively registered 
and updated to reflect the study extension with the clini-
caltrials.com (NCT01647958). The authors had access to 
the study data, and the coauthors reviewed and approved 
the final manuscript.
Study Patients
All included patients were chronic GERD sufferers with 
daily troublesome regurgitation and/or atypical symp-
toms refractory to PPI therapy, pathological esophageal 
acid exposure confirmed by 48-hour pH monitoring off 
PPI therapy (percentage time pH <4 greater than 5.3%), 
and history of PPI use for at least 6 months.3 Patients with 
hiatal hernia >2 cm, Hill grade III or IV, esophagitis of 
grade C or D (Los Angeles classification), and Barrett’s 
esophagus >2 cm were excluded from randomization. 
Furthermore, patients with class 2 or 3 obesity (body 
mass index [BMI] > 35 kg/m2), esophageal motility dis-
orders, and previous gastric or esophageal surgery were 
also excluded.
Study Procedures
Prerandomization patient characteristics, baseline 
assessments, TIF procedure data, and follow-up evalua-
tions up to 3 years postprocedure have been previously 
reported.3-5 This included symptomatic assessment with 
validated disease-specific questionnaires on and/or off 
PPI therapy as well as esophagogastroduodenoscopy 
and 48-hour pH-metry off PPIs at prespecified time 
intervals.5 All patients in this study underwent the stan-
dard TIF 2.0 procedure using the EsophyX
2
 device 
under general endotracheal anesthesia.5 The TIF 2.0 
procedure created a full-thickness, partial gastroesopha-
geal fundoplication secured above the Z-line with poly-
propylene “H” fasteners that were delivered through the 
thickness of the apposed stomach and esophageal walls.
The length and circumference of newly built TIF 
2.0 gastroesophageal valves was determined by per-
forming an immediate postprocedure endoscopy and 
using well-described standardized methods. The valve 
length is measured as the distance in centimeters from 
the apex of the fundus to the valve lip, as measured at 
the incisors in endoscopic retroflexion.6 The valve cir-
cumference is defined as the distance in degrees 
between the 2 most distant fasteners used to secure the 
fundoplication.7 The count of contributing fasteners 
was conducted during the immediate postprocedure 
endoscopy.
Assessments and Follow-up
The TEMPO trial was initially designed to follow enrolled 
patients for up to 3 years after TIF. After completion of 
the 3-year follow-up, all investigators agreed to continue 
following the patients for an additional 2 years. Data 
were collected on elimination of troublesome symptoms, 
PPI use, reoperation, adverse events, and patient 
satisfaction.
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Troublesome symptoms were defined according to the 
Montreal consensus definition as mild symptoms occur-
ring 2 or more days a week, or moderate to severe symp-
toms occurring more than 1 day a week.8 In the TEMPO 
trial, the Reflux Disease Questionnaire (RDQ) was used 
to assess elimination of troublesome regurgitation.3-5 
RDQ is a 12-item questionnaire that was designed to 
assess the frequency and severity of heartburn (4 items 
measuring the frequency and severity of pain and burning 
behind the breastbone), regurgitation (4 items measuring 
the frequency and severity of acid taste in the mouth and 
movement of the material upward from the stomach), and 
dyspeptic complaints (4 items measuring the frequency 
and severity of pain or burning in the upper stomach).9 
Response options range from 0 (not present) to 5 (daily) 
for frequency and 0 (not present) to 5 (severe) for sever-
ity. Each patient’s score is calculated as the mean of item 
responses, with higher scores indicating more frequent 
and/or severe symptoms.
The Reflux Symptom Index (RSI) questionnaire was 
used to assess elimination of atypical symptoms. RSI is a 
9-item validated questionnaire used to measure atypical 
GERD symptoms such as hoarseness, throat clearing, 
excess throat mucus, dysphagia, and cough.10 The scale 
for each individual item ranges from 0 (no problem) to 5 
(severe problem), with a maximum total score of 45 and a 
normality threshold of ≤13.
GERD Health-Related Quality of Life (GERD-HRQL) 
was used to evaluate typical GERD symptoms, quality of 
life, and patient satisfaction with their current health con-
dition. A higher total GERD-HRQL score (range from 0 
to 50) indicates more severe GERD.11
PPI use was self-reported by patients as complete ces-
sation, occasional use (<3 d/wk), or daily use. Individual 
investigators reported adverse events and reoperation 
rates. Patient satisfaction with their current health condi-
tion was reported as part of the GERD-HRQL, with 3 
possible answers: satisfied, neutral, or dissatisfied.
For the purpose of cost analysis, the Optum healthcare 
database (data from 2011 to 2013) was used to determine 
cost and resource utilization for TIF and LNF up to a 
2-year follow-up. Standardized costs were computed for 
inpatient and outpatient visits and medical therapy.
Primary End Points
Primary end points were elimination of troublesome 
regurgitation and elimination of all troublesome atypical 
symptoms at the 5-year follow-up as evaluated by the 
RDQ and RSI, respectively.
Secondary End Points
Secondary end points were improvement in symptom 
scores (RDQ, RSI, GERD-HRQL), PPI use, reoperations, 
and satisfaction with current health condition. We also 
compared the cost-effectiveness of TIF versus LNF based 
on data obtained from the Optum group.
Data Collection and Statistical Analyses
An independent clinical research organization collected 
the patient-reported outcomes and entered the data points 
into the password-protected electronic database. 
Postoperative data at 1-, 3-, and 5-year intervals were 
compared with preoperative data using the repeated-
measures analysis of variance (ANOVA) followed by the 
post hoc Tukey-Kramer honestly significant difference 
multiple comparison procedure. In general, continuous 
variables were reported as means (SDs); categorical 
variables were reported as percentage, counts, and 95% 
CIs and were tested for significant difference using 
McNemar’s test. All 3 TIF failures (patients who under-
went a revisional procedure) were included in the analy-
ses and were assigned the worst outcomes observed 
during the study from the timing of revisional surgery 
going forward. The statistical significance was prespeci-
fied by a P value of <.05.
Results
A total of 196 patients with chronic GERD were assessed 
for study eligibility between June and August 2012. Of 
these 196, 32% (63) met the study inclusion/exclusion 
criteria and were randomized (40 patients into the TIF 
group and 23 patients into the PPI group).3 The most 
commonly cited cause for ineligibility was the absence of 
pathological distal esophageal acid exposure (Figure 1). 
Of the randomized patients, 70% (44/63) completed the 
5-year follow- up assessments.
Patient Demographics and Baseline 
Characteristics
The study population (n = 60) was 55% female (33) and 
45% male (27%). The average age at the time of enroll-
ment was 51.5 ± 10.3 years. The largest age segment was 
the 50- to 65-year-old segment (52%, 31). Of the remain-
ing patients, 40% (24) were younger than 50 years, and 
only 8% (5) were older than 65 years. The average BMI 
was 28.5 ± 3.7 kg/m2. GERD symptom duration was 11.2 
± 9.8 years; PPI therapy duration was 8.6 ± 6.5 years. 
Only 2% (1) of patients had the short-segment variant of 
Barrett’s esophagus.
Safety and Procedure Data
No SAEs reported or any other complication associ-
ated with the TIF 2.0 procedure occurred in this study.3-5 
As assessed by immediate postprocedure endoscopy, 
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TIF 2.0 created valves with an average length of 2.8 ± 
0.5 cm and a circumference of 290° ± 20°. On average, 
21 ± 4 fasteners were used to secure the newly created 
valves.
Two revisional interventions were previously reported 
(1 Dor fundoplication in the second year and 1 LNF in the 
third year).5 Since that last report, 1 additional patient 
underwent a reoperation (LNF). Therefore, the reopera-
tion rate for this cohort was 5% (3/60). All surgical revi-
sions were performed on patients with recurrent daily 
troublesome GERD symptoms that persisted on PPI ther-
apy. Endoscopic findings for the 3 patients undergoing 
revisional surgery included recurrent hiatal hernia and 
varying degrees of disruption of the TIF 2.0 valve. Before 
revisional procedures, all patients had abnormal distal 
esophageal acid exposure. At baseline, in addition to 
daily troublesome regurgitation and/or atypical symp-
toms, all 3 patients suffered from daily troublesome 
heartburn on twice-daily PPI therapy. Severity of GERD 
in these patients was further confirmed by percentage 
total time of pH <4 before the TIF 2.0 procedure (7.5, 
16.8, and 19.5).
Primary Clinical End Point
Of 44 patients who underwent the 5-year follow-up, 98% 
(43) suffered from troublesome regurgitation on PPI ther-
apy at screening. At the 5-year follow-up, elimination of 
troublesome regurgitation was achieved in 86% of 
patients (37/43, 95% CI = 72%-94%). Similar findings 
were observed at the 1- and 3-year follow-ups (Figure 2). 
Elimination of troublesome atypical symptoms occurred 
in 80% of patients at 5 years (31/39, 95% CI = 64%-
89%), 88% at 3 years (42/48, 95% CI = 75%-95%), and 
82% at 1 year (45/55, 95% CI = 70%-90%). No statisti-
cally significant differences in elimination of trouble-
some regurgitation or atypical symptoms were found 
between assessments at years 1, 3, and 5. Results are 
reported regardless of PPI use at the time of assessment 
(on or off PPI therapy).
Figure 1. Study flowchart of treated and analyzed patients. Of the 85 patients not meeting eligibility criteria, 45% (38/85) had 
normal pH test, 36% (31/85) had hiatal hernia >2 cm in axial length or greatest transverse dimension, 13% had Hill grade >II, 2% 
had reflux esophagitis grade C or D (Los Angeles classification), 2% had body mass index >35 kg/m2, and 1% (1/85) had Barrett’s 
esophagus >2 cm.5 Additionally, 32 patients declined to participate, and 16 were excluded for other reasons.3
Abbreviation: LNF, laparoscopic Nissen fundoplication.
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Secondary End Points
The total regurgitation score (assessed by RDQ) improved 
significantly by falling from 3.0 on PPIs at screening to 
0.7 at the 5-year follow-up (P < .001). There was no statis-
tically significant difference between the total regurgita-
tion scores at the 1-, 3-, and 5-year follow-up (Figure 3). 
The total RDQ score improved significantly by decreasing 
from 3.0 at screening to 0.8 at the 1-year, 0.6 at the 3-year, 
and 0.7 at the 5-year follow-up (P <.001 in all cases vs 
screening).
The total RSI score improved by decreasing from 22.2 
at screening to 6.3 at the 5-year follow-up (P < .001). 
There was no statistically significant difference between 
the total RSI scores at 1-, 3-, and 5-year assessments 
(Figure 4). The improvement in total GERD-HRQL score 
was stable between the 1-, 3-, and 5-year follow-up 
assessments (Figure 5).
All patients were on daily PPI therapy at screening. At 
the 5-year follow-up, 34% (15/44, 95% CI = 22%-49%) 
of patients were on daily PPI therapy. An additional 20% 
(9/44, 95% CI = 11%-35%) of patients were taking PPI 
medication occasionally. Therefore, complete cessation 
of PPI therapy was achieved in 46% (20/44, 94% CI = 
32%-60%) of patients who completed the 5-year follow-
up (Figure 6).
Patient satisfaction with current health condition, as 
assessed by GERD-HRQL, before treatment was 2% 
(1/60, 95% CI = 0%-10%) and improved to 75% (45/60, 
Figure 2. Elimination of troublesome regurgitation, as 
assessed by the Reflux Disease Questionnaire at the 1-, 3-, 
and 5-year follow-ups.
Figure 3. Regurgitation score, as assessed by the Reflux 
Disease Questionnaire, at screening and the 1-, 3-, and 5-year 
follow-ups.
Abbreviation: PPI, proton pump inhibitor.
Figure 4. Reflux Index Score at screening and 1-, 3-, and 
5-year follow-up assessments.
Abbreviation: PPI, proton pump inhibitor.
Figure 5. Gastroesophageal Reflux Disease Health-Related 
Quality of Life (GERD-HRQL) questionnaire, at screening and 
1-, 3-, and 5-year follow-up assessments.
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95% CI = 63% -84%) at 1 year, to 83% (43/52, 95% CI = 
70%-91%) at the 3-year follow-up, and to 70% (31/44, 
95% CI = 56%-82%) at 5 years (P <.001 vs screening in 
all cases).
At 3 years post-TIF, all esophageal pH parameters, 
with the exception of duration of longest reflux, improved 
significantly as compared to baseline, with 40% (16/40) 
of patients achieving pH normalization.5 Of the 24 
patients with elevated levels of distal esophageal acid 
exposure at 3 years (defined as percentage total time of 
pH <4 greater than 5.3%, as measured by 48-hour pH 
testing), 22% (5/24) were not available for the 5-year 
follow-up. Of the remaining 19 patients, 63% (12/19, 
95% CI = 41%-81%) reported complete cessation of PPI 
therapy at 5 years; 16% (3/19, 95% CI = 5%-38%) 
reported taking PPIs occasionally, and 21% (4/19, 95% 
CI = 8%-44%) reported taking PPIs daily.
Cost Analysis
In the Optum database, 2734 LNF patients and 73 TIF 
patients were available for the cost analysis. The aver-
age total cost over 2 years per LNF patient was $99 256, 
as compared with $71 691 per individual TIF patient 
(Table 1). The total average health care utilization for 
LNF and TIF is shown in Figure 7.
In the subgroup of patients with resource utilization in 
the top quartile (ie, most refractory PPI patients), the 
average cost of care (preindex, first and second year post-
procedure) summed over a 2-year period for a LNF 
patient was $124 000, as compared with $66 000 for a 
TIF patient.
Discussion
The TEMPO trial is the first trial to assess the long-term 
outcomes (5-year follow-up) of the TIF 2.0 procedure in 
a US patient population. Patients suffering from trouble-
some regurgitation and atypical symptoms despite opti-
mized acid-reducing therapy represent a common clinical 
challenge. This validated the crossover randomized 
design of this trial, allowing patients in the PPI arm to 
undergo TIF 2.0 after their 6-month follow-up. Of note, 
all of them chose this option, recognizing that the TIF 2.0 
procedure may offer a valuable alternative.
The major contribution of this report is that it offers 
conclusive evidence that the early benefits reported with 
the TIF 2.0 procedure in previous shorter-term prospec-
tive multicenter randomized reports3-5 and prospective 
multicenter observational studies12-14 are sustained at the 
5-year follow-up. This is a milestone that has not been 
achieved by previous GERD endoluminal therapies (eg, 
EndoCinch, Enteryx, Gatekeeper, NDO Plicator, ELF, 
and TIF 1.0), which, with the exception of the Stretta pro-
cedure, are no longer available because of safety con-
cerns and/or lack of effectiveness. The quality and 
durability of the long-term symptomatic outcomes 
achieved in this study set apart the TIF 2.0 procedure 
from these earlier GERD treatment modalities. These 
results were achieved without unwanted SAE and post-
fundoplication side effects.5 Importantly, the elimination 
of regurgitation, atypical symptoms, and heartburn, as 
evaluated by validated, disease-specific questionnaires 
(RDQ, RSI, GERD-HRQL), was maintained without sig-
nificant deterioration over time. Therefore, this study 
establishes the ability of the TIF 2.0 procedure to provide 
long-term and durable resolution of troublesome GERD 
symptoms, improvement of quality of life, and reduction 
in PPI utilization in well-selected chronic GERD patients.
Our study design included patients who were selected 
to demonstrate that the TIF 2.0 procedure would be ben-
eficial for a subset of chronic GERD patients who failed 
maximal medical therapy (hiatal hernia ≤2 cm, esophagi-
tis Los Angeles grade A or B, Hill grade valve I or II). 
These patients had been experiencing intractable symp-
toms and sought a minimally invasive surgical cure with-
out side effects. The TIF 2.0 procedure has repeatedly 
proven to avoid postfundoplication symptoms such as gas 
bloat, flatulence, dysphagia, and diarrhea.5 The authors 
reiterate that comparable results can only be achieved by 
expert endoscopists with appropriate training in the stan-
dardized TIF 2.0 technique and by adhering to stringent 
selection criteria similar to what was used in this study.
The reoperation rate in this report was determined to 
be 5% (3/60) after 5 years, which is comparable to the 
published rates of reoperation after LNF (3%-6%).15,16 In 
Figure 6. Percentage of patients on daily proton-pump 
inhibitor (PPI) therapy at screening and 1-, 3-, and 5-year 
follow-up assessments.
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our study, 3 patients underwent Laparoscopic Nissen (2) 
and Dor (1) fundoplication post-TIF without difficulty, as 
was previously suggested by others.17 In contrast, studies 
with earlier iterations of the device and techniques no 
longer used (ELF and TIF 1.0) reported higher rate of 
reoperations (11%-52%).18-20 Additionally, the higher 
reported reoperation rates from the European studies can 
be attributed to patient selection because patients with 
large hiatal hernias (>2 cm), Hill grade valves III and IV, 
and esophagitis C or D were often enrolled.
Limitations of the study include the relatively small 
number of patients, which can be partially explained by 
the challenges involved in enrolling patients with such 
highly selective criteria. The study was, however, appro-
priately powered for statistical significance and had a 
respectable follow-up rate of 70% at 5-year assessment. 
We could also be criticized for not performing functional 
tests and endoscopies at the 5-year mark, though they 
were performed and reported in the 3-year follow-up.5 
We note that a poor correlation between postintervention 
GERD symptoms and physiological parameters has con-
sistently been reported with all therapies, including tradi-
tional antireflux surgery,21,22 the TIF procedure,5,23 and 
during PPI therapy (17% to 80% of patients demonstrated 
abnormal esophageal acid exposure while being asymp-
tomatic on PPI therapy).3,24-27 An additional potential 
limitation of this study is that the results are reported 
regardless of PPI use at the time of postprocedure assess-
ment (on or off PPI therapy). We felt justified to use this 
methodology because all patients in the study experi-
enced daily troublesome regurgitation and/or atypical 
symptoms on optimized PPI therapy before the TIF 2.0 
procedure. Achieving control of troublesome symptoms 
and improving quality of life with the use of PPIs after an 
endoscopic antireflux procedure in patients whose symp-
toms were refractory to high-dose PPIs before intervention 
should not necessarily be considered a treatment failure.4 
In these cases, the TIF procedure may be viewed as a use-
ful therapeutic adjunct to PPIs.
Although every patient enrolled in the TEMPO trial 
experienced intractable GERD symptoms despite daily 
PPIs (per inclusion criteria), more than two-thirds of 
patients remained off daily PPIs 5 years after undergoing 
the TIF procedure. Others have suggested that return to 
PPI utilization is a poor indicator of recurrent GERD.28 In 
our study, patients who were still on occasional or daily 
PPIs had benefited from improved symptomatic control 
after TIF 2.0, with 95% of patients enrolled not having 
sought corrective surgery after 5 years.
The TIF 2.0 procedure appears to be cost-effective. 
Medicare data suggest that the average reimbursement 
for a TIF procedure ($4, 510.81) is about half the rate for 
a LNF ($8, 573.99). A simulation applying these reim-
bursement rates to the 60 TEMPO patients (who were 
candidates for either procedure) reveals a potential proce-
dure-related savings of $238 543.40 for performing TIF 
2.0 instead of LNF. Considering that the preprocedure 
evaluation is the same for the TIF candidates and the LNF 
candidates, and that the reoperation rate established in 
this study for TIF is similar to that of LNF, we believe 
that TIF may be a cost-effective alternative to LNF. In the 
top quartile of medical resource utilization, such as in 
GERD patient populations with similar characteristics as 
our TEMPO patients, the potential savings may be even 
more significant. Indeed, in that subgroup, the approxi-
mate total accrued cost reached $124 000 for a single 
LNF patient versus $66 000 for TIF for the first 2 years 
postprocedure. Out of the 63 patients enrolled in this 
study and who underwent the TIF procedure, 5% had cor-
rective surgery within 5 years, leaving 95% of patients 
Table 1. Average Cost, With Breakdown by Category, 
Associated With TIF 2.0 and LNF, as Accrued Over a 
2-Year Follow-up Period (Data Obtained From the Optum 
Database).
TIF ($) LNF ($)
Office 7483 8474
Inpatient (hospital) 21 956 44 652
Emergency room 1162 961
Outpatient (hospital) 23 837 23 540
Ambulatory surgical center 3244 2737
Independent laboratory 1384 718
Pharmacy 11 136 12 675
Other 1489 5500
Total 71 691 99 256
Abbreviations: TIF, transoral incisionless fundoplication; LNF, 
laparoscopic Nissen fundoplication.
Figure 7. The Optum database average utilization of health 
care resources (number of claims) for laparoscopic Nissen 
fundoplication (LNF) and transoral incisionless fundoplication 
(TIF) over 2 years.
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who underwent a less-invasive procedure, with virtually 
no side effects and at a significant overall cost savings 
compared with more invasive GERD surgery.
Based on these results and the authors’ personal expe-
rience, and in an attempt to define the role of TIF in the 
antireflux armamentarium, we suggest that in the appro-
priate patient population, the TIF 2.0 procedure could be 
considered the definitive alternative therapy to PPIs in a 
majority of patients undergoing the procedure. Indeed, 
our study shows that at 5 years, a majority of patients had 
enjoyed the combined benefits of not having undergone 
any kind of additional corrective surgery, not being back 
on daily dose of PPIs, experiencing complete resolution 
of their troublesome symptoms, and being satisfied. In a 
minority of patients, it appears that TIF 2.0 represented a 
useful adjunct therapy to be used in conjunction with 
various regimens of acid-reducing therapy. In this sub-
group of patients, our study shows that the TIF procedure 
helped eliminate or improve difficult-to-control symp-
toms such as regurgitation and atypical symptoms that 
had been intractable and refractory to PPIs prior to the 
procedure. Finally, in a very small group of patients, esti-
mated at approximately 5% after 5 years, the procedure 
would have represented a noninvasive first-line therapy 
without “burning any bridges” or compromising the abil-
ity to perform additional surgery such as a LNF.15
Conclusions
Five years after undergoing TIF 2.0, the great majority 
of TEMPO trial patients experienced durable elimina-
tion of all types of troublesome GERD manifestations, 
including regurgitation and atypical symptoms. There 
were no SAEs or any safety concerns associated with 
the TIF 2.0 procedure. It also appears that in the appro-
priate patient population, the TIF 2.0 procedure could be 
a cost-effective alternative to LNF.
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